Targeting The OPN-CD44 Axis as a Therapeutic Strategy to Chemo-sensitize Ovarian Tumors

Targeting The OPN-CD44 Axis as a Therapeutic Strategy to Chemo-sensitize Ovarian Tumors

Document Type

Poster

Publication Date

10-1-2025

Abstract

Epithelial ovarian cancer is one of the most aggressive gynecological cancers with a 49% 5-year survival rate due to its late diagnosis and its development of resistance to standard chemotherapy such as platinum based drugs. By chemosensitizing the ovarian cancer cells, existing therapies would be more effective in treating the disease and potentially reduce the recurrence risk. Our goal was to investigate the role of OPN in driving chemoresistance in ovarian cancer patients and to create recycling therapeutic antibodies to block the interaction between OPN and the CD44 integrin on the ovarian cancer cells. By blocking the interaction, we aim to reduce and eliminate the chemoresistance of the cells to chemotherapy.

Department

Department of Radiation Oncology, Stanford School Of Medicine, Palo Alto, CaliforniaDepartment of Obstetrics & Gynecology, Stanford School of Medicine, Palo Alto, CaliforniaDepartment of Stem Cell & Regenerative Medicine, Stanford School of Medicine, Palo Alto, California

Project Mentor

Dr. Cristabelle De Souza

Funding and Acknowledgements

DePauw grants help fund this project.

Targeting The OPN-CD44 Axis as a Therapeutic Strategy to Chemo-sensitize Ovarian Tumors

Share

COinS